Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Relapsed or Refractory DLBCL
NCT00392496Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2007
- Primary completion
- Jan 2012
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), sponsored by National Cancer Institute. Primary endpoints: Objective Tumor Response at 3 years, Toxicity at 3 years and 1 more. Started Feb 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT00392496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392496.